“The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance” Dr Gilles Courtemanche, BIOASTER Antimicrobials Program Head is co-author of a scientific publication...
BIOASTER in collaboration with Cochin Hospital and the REALISM project consortium (study of the pathophysiology of intensive care patients and on biomarkers), has just published the article entitled “Assessing the...
2 new application notes from Bioassays, Microsystems and Optical engineering unit. LABEL-FREE QUANTITATIVE PHASE IMAGING FOR SINGLE -CELL PHENOTYPING : Drug effect characterization form Digital In-Line Holographic imaging of bacteria....
An international public-private collaborative study coordinated by BIOASTER has highlighted the value of blood-based transcriptomic biomarkers to improve early Tuberculosis (TB) diagnosis.
Call for a unique opportunity in antibiotic community! The GNA NOW consortium (EU project) is looking for a novel antibiotic compound to progress to a clinical candidate. To find out...
BIOASTER, the French Technology Research Institute for Microbiology and Infectious Diseases, has today announced a new collaboration with Evotec in the field of chikungunya infection diagnosis.
Kaleido Biosciences and BIOASTER are glad to announce the successful completion of a collaborative project that provided new insights into ways Kaleido’s Microbiome Metabolic Therapies (MMT™) modulate the integrity and function of...
PiLeJe Laboratoire to collaborate with BIOASTER to investigate the health potential of a probiotic selection Pileje Laboratoire, a French company leader in probiotic-based dietary supplements in Europe and specialized in...
An opinion review from AMR Insight ambassadors with Dr Gilles Courtemanche, Associate Director, Antimicrobials Unit @bioaster Authors: Gilles Courtemanche, Rohini Wadanamby, Amritanjali Kiran, Luisa Fernanda Toro-Alzate, Mathew Diggle, Dipanjan Chakraborty,...
Hopefully, we will have a chance to share updates face to face, in the meantime we are happy to highlight some of the 2020 Antimicrobials Program achievements. If this should...
By continuing browsing this website, you accept the use of cookies or other tracers for statistics of visits to optimize the functionality of the site, and or privacy policy. AcceptRejectRead More
Privacy & Cookies Policy
Privacy Overview
This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
